Ainos, Inc. is a dual-platform AI and biotech company advancing SmellTech and immune therapeutics. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. It is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions.
Growing
The company is in a growing phase, with the latest annual income totaling USD 124.16K.
Undervalued
The company’s latest PE is -0.69, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 300.01K shares, increasing 30.26% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.88.